ANI Pharmaceuticals 2022 H.C. Wainwright Bioconnect Conference Presentation

ANI Pharmaceuticals presented at the H.C. Wainwright Bioconnect Conference in January 2022, showcasing its diversified biopharma portfolio spanning rare disease, generics, established brands, and CDMO services. The company highlighted its transformational opportunity with Cortrophin Gel, approved by the FDA in October 2021, targeting the $770M ACTH market, while maintaining a track record of strategic acquisitions and sustainable growth.